1-hour plasma glucose useful tool for predicting risk of hepatic fibrosis

USA: 1-hour plasma glucose (1-h PG) is a useful tool for distinguishing subjects with normal glucose tolerance (NGT) or impaired fasting glucose (IFG) at increased risk of hepatic fibrosis needing further evaluation with elastography, research finds. The study appears in Diabetes Research and Clinical Practice on June 27, 2022. 

People with high 1-hour plasma glucose (1-h PG>155mg/dl;8.6mmol/l) during an oral glucose tolerance test have been reported to be at increased risk of type 2 diabetes (T2D) and cardiovascular complications, mortality, and hepatic steatosis. However, there is no clarity on the clinical relevance of 1-h PG for the severity of hepatic fibrosis risk. 

Ram Jagannathan, Department of Medicine, Division of Hospital Medicine, Emory University School of Medicine, Atlanta, GA, USA, and colleagues used cross-sectional data of the CATAMERI study (n=2335). Participants underwent liver enzyme determinations, anthropometric measurements, cardiometabolic profiling, and a 75-gram oral glucose tolerance test, including fasting, 1-h, and 2-h PG determinations, and measurement of FIB-4 score to assess the degree of hepatic fibrosis. The risk of advanced hepatic fibrosis with worsening glycemic status was evaluated using multivariable logistic regression analysis.